Blog
New FDA guidance: cell therapies and patient identifiers
When the US Food and Drug Administration (FDA) recently made two draft guidance documents for the cell and gene therapies available for comment, the Vineti team was quick to scan for one three-letter phrase that is core to our mission – COI.
Supply chain vs. value chain: need-to-know essentials
In a recent blog post about Quality Risk Management, we talked about the importance of considering the entire “value chain” when...
Design for personalized therapies: reframing “delight” as the goal
Sometimes, in the world of UX and product design, “delight” means getting out of the way. Read about general approaches...
The road ahead for #regenmed
This fall, it will be 15 years since regenerative medicine faced a crisis of funding and support in the United...
In September, here’s why it’s all about data management
Next month, my colleagues at Vineti and I will be speaking, writing, and presenting on a topic of critical importance...
September events! A Big Data webinar with Dr. Scott Burger, and a talk at CAR-TCR Summit
September marks the start of the autumn conference season in cell and gene therapy, and this fall I’m looking forward to...
Patient experiences – three inspiring stories
Every person working in cell therapies and gene therapies does so for the potential to improve patients’ lives. Emily Whitehead,...
Cell therapy and gene therapy news: updates from some of our biopharmaceutical partners
We’re always excited to support the innovation pursued by our biopharmaceutical partners as they work toward improved patient outcomes. Here...
Cell therapy and gene therapy — three summer reads that “get it”
In cell therapy, gene therapy, and personalized cancer vaccines, most media coverage understandably focuses on the medicine — the amazing...
Supply chain management readiness, Part 4: quality risk management
Note: this post is the last of a four-part series on supply chain planning for personalized therapies such as cell...
Vineti selected as Technology Pioneer by the World Economic Forum
Each year, the World Economic Forum welcomes leading early-stage companies from around the world into its Technology Pioneers community. Today, I’m both thrilled and...
Reasons for hope on the journey to personalized medicine “kaizen”
One of my very favorite writers, Siddhartha Mukherjee, published an article in The New Yorker this month on the importance of pursuing kaizen in balance...
Vineti joins the leadership of the Standards Coordinating Body
At Vineti, we’re pushing every day to help the field of advanced therapies — cell therapy, gene therapy, personalized cancer...